Bolsa ES - Gráfico Interactivo de Análisis Técnico de Celgene Corporati [CELG]

Busque más análisis técnicos aquí en nuestro foro: Análisis Técnicos

Nota: Los datos después de 2012-05-16 son temporales y pueden tener un valor de Apertura incorrecto hasta nueva actualización...
Cambiar para Gráfico Estático de Celgene Corporati

Celgene Corporati - [Ticker: CELG]
Última Transacción	68,410	Hora de Cotización	2012-05-18 - 15:13
Variación	-0,660 (-0.96%)	Rango 52 Semanas	[51,700 - 80,420]
Máximo	69,360	Mínimo	68,200
Volumen	943.469	Volumen Medio (3m)	2.961.670
Demanda / Oferta	68,390 x 200 - 68,400 x 100	Yield	N/A
Cierre Anterior	69,070	PER	22,02%
Apertura	69,280	EPS	3,21
Fecha Ex-Dividendo	N/A	Fecha Dividendo	N/A
Capitalización Bursátil	31	Objetivo Estimado 1 Año	84,280
Nota: Los datos pueden tener un retraso de algunos minutos.

Noticias de Celgene Corporati [CELG]: (ordenadas por relevancia)

Cinco vías para 'atacar' el sector de la biotecnología
elEconomista.es
El caso más claro es el de Celgene (CELG.NQ), que mientras que se ha anotado un 4,6% desde el 1 de enero, ha visto caer su PER (veces que el beneficio está contenido en el precio) casi un 2%. Además, es una de las que cuenta con mayor potencial y es la ...

4-Star Stocks Poised to Pop: Celgene
DailyFinance
By Brian D. Pacampara, The Motley Fool Based on the aggregated intelligence of 180000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Celgene (NAS: CELG) has earned a respected four-star ...

y más »

Celgene Retains Neutral Rec
Zacks.com
We are maintaining our Neutral recommendation on Celgene Corporation (CELG - Analyst Report) with a target price of $74.00. Celgene disclosed its first quarter 2012 results last month. The company earned 96 cents on an adjusted basis during the quarter ...

y más »

Zacks Reaffirms Neutral Rating on Celgene (CELG)
Junction Report
Celgene (NASDAQ: CELG)'s stock had its ?neutral? rating reiterated by Zacks in a research note issued to investors on Friday. They currently have a $74.00 price target on the stock. Zacks' analyst wrote, ?Celgene's first quarter 2012 adjusted earnings ...

y más »

The Star-Ledger - NJ.com

Celgene profit rose 57% on sales growth
MarketWatch
By Tess Stynes Celgene Corp.'s (NASDAQ:CELG) first-quarter earnings rose 57% as the biopharmaceutical company posted broad sales growth and stronger margins. Shares of Celgene, which affirmed its 2012 guidance, were down 2.5% at $76 in premarket ...
Celgene Q1 Results Miss Estimates; But Reaffirms 2012 OutlookNASDAQ
Celgene Reports First Quarter 2012 Operating and Financial ResultsSunHerald.com
Epizyme builds epigenetics lineup with $90M Celgene scoreFierceBiotech
Daily Markets
los 49 artículos informativos »

FDA: Celgene Drug Revlimid Increases Risk Of Certain New Cancers
Fox Business
WASHINGTON ? The Food and Drug Administration said certain patients treated with Celgene Corp.'s (CELG) cancer drug Revlimid have an increased risk of developing some new types of cancers. Revlimid is approved to treat patients with multiple myeloma, ...
Celgene Sets The Stage For Patient InvestorsSeeking Alpha

los 15 artículos informativos »

Celgene Corporation Announces Appointment of Thomas M. Moriarty as General Counsel
MarketWatch (press release)
SUMMIT, NJ, May 07, 2012 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ:CELG) today announced the appointment of Thomas M. Moriarty as General Counsel and Corporate Secretary. In this position, he will be responsible for global legal strategy at ...

y más »

Celgene Corporation Announces Appointment of Thomas M. Moriarty as General Counsel
SunHerald.com
SUMMIT, NJ -- Celgene Corporation (NASDAQ: CELG) today announced the appointment of Thomas M. Moriarty as General Counsel and Corporate Secretary. In this position, he will be responsible for global legal strategy at Celgene and will serve on the ...

y más »

Celgene Corporation to Present at Two Upcoming Investor Conferences
MarketWatch (press release)
SUMMIT, NJ, May 04, 2012 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ:CELG) announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the Company's Web site at ...

y más »

FDA: Celgene Drug Revlimid Increases Risk Of Certain New Cancers
Wall Street Journal
By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--The Food and Drug Administration said certain patients treated with Celgene Corp.'s (CELG) cancer drug Revlimid have an increased risk of developing some new types of cancers.

y más »

The Star-Ledger - NJ.com

Celgene 1Q Profit Rose 57% On Sales Growth; Plans Venture With Epizyme
Wall Street Journal
Celgene Corp.'s (CELG) first-quarter earnings rose 57% as the biopharmaceutical company posted broad sales growth and stronger margins. Shares of Celgene, which affirmed its 2012 guidance, were down 2.5% at $76 in premarket trading as the results ...
UBS Suggest Buying Celgene (CELG) on Pullback; Key Takeaways From Conference CallStreetInsider.com (subscription)

los 5 artículos informativos »

NEJM publishes results from Celgene's REVLIMID phase III studies on MM
News-Medical.net
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that results from three phase III studies evaluating the use of continuous REVLIMID ® (lenalidomide) treatment in newly diagnosed multiple myeloma (MM) ...
US FDA warns on safety of Celgene's Revlimid; new Ph III trial resultsThe Pharma Letter

los 4 artículos informativos »

Forbes Earnings Preview: Celgene
Forbes
By Narrative Science Wall Street is expecting higher profit for Celgene (CELG) when the company reports its first quarter results on Thursday, April 26, 2012. The consensus estimate is calling for profit of $1.02 a share, a rise from 71 cents per share ...

y más »

Celgene Rating Lowered to Neutral at Bank of America (CELG)
Daily Political
Celgene (NASDAQ: CELG) was downgraded by equities researchers at Bank of America (NYSE: BAC) from a ?buy? rating to a ?neutral? rating in a report issued on Friday. Shares of Celgene traded down 0.62% during mid-day trading on Friday, hitting $72.925.

y más »

Celgene Stock Drops As Q1 Earnings Miss Expectations
Investor's Business Daily
By AMY REEVES, INVESTOR'S BUSINESS DAILY Posted 04/26/2012 10:05 AM ET Leading biotech Celgene (CELG) got stopped in its tracks Thursday morning as it missed Wall Street's first-quarter estimates on both the top and bottom lines.

y más »

Para más noticias de Celgene Corporati hacer clic aquí:
Noticias de Celgene Corporati